Overview

Double-blind Comparative Study of TAK-875

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Criteria
Inclusion Criteria:

1. The participant is an outpatient.

2. The participant signs and dates a written, informed consent form and any required
privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or
any serious pancreatic or hematological disease.

2. The participant is considered ineligible for the study for any other reason by the
investigator or sub-investigator.